Boutique trends we're watching in 2024
Federal reserve policies, M&A activity, and names we're following...
Biotech has roared back and seen a strong start to the new year. Since November, in less than 3 months, the XBI is up 32%. The rally has been driven primarily by an expected shift in Fed interest rate policy, continued M&A activity from big pharma, and generalist investors re-entering the space. The FOMO factor is real and something that should continue…